Research Article

Analysis of the difference in SLCO1B1 and APOE gene polymorphisms between Mongolian and Han populations

Department of Clinical Laboratory, Ordos Central Hospital, Ordos, Inner Mongolia, 017000, China

‡Authors contributed equally

Search for more papers by this author

Liping Guo‡

Department of Dermatology, Ordos Central Hospital, Ordos, Inner Mongolia, 017000, China

‡Authors contributed equally

Search for more papers by this author

Xiaoxian Dong

Department of Dermatology, Ordos Central Hospital, Ordos, Inner Mongolia, 017000, China

Search for more papers by this author

Li Pan

Department of General practice, Ordos Central Hospital, Ordos, Inner Mongolia, 017000, China

Search for more papers by this author

Yueqin Hai

Inner Mongolia Medical University, Hohhot, Inner Mongolia, 010000, China

Search for more papers by this author

Xiaoxiao Chen

Baotou Medical College, Inner Mongolia University of Science & Technology, Baotou, Inner Mongolia, 014000, China

Search for more papers by this author

Baosheng Duan

*Author for correspondence: Tel.: +86 0477 8119021;

E-mail Address: duan_bs@126.com

Department of Clinical Laboratory, Ordos Central Hospital, Ordos, Inner Mongolia, 017000, China

Search for more papers by this author

Published Online:8 Sep 2022https://doi.org/10.2217/pgs-2022-0072

View article

Abstract

Objective: To analyze SLCO1B1 and APOE polymorphisms and their clinical significance in the Mongolian and Han populations in Ordos, Inner Mongolia. Methods: Mongolian patients (n = 200) with cardiovascular disease admitted to our hospital from January 2018 to December 2020 were selected as the Mongolian population group. Han patients (n = 200) with cardiovascular diseases admitted during the same period were selected as the Han population group. Mutations in SLCO1B1 and APOE were detected by real-time fluorescence qPCR, and the differences between the two groups were analyzed. Results: The nucleotide polymorphisms of SLCO1B1 and APOE in the Mongolian and Han populations were consistent with the Hardy–Weinberg law. There were significant differences in gender, age, BMI, hypertension, alcohol consumption, dyslipidemia and low-density lipoprotein cholesterol levels between the two groups. APOE genotypes were classified according to those related to the efficacy of statins and the risk of atherosclerosis, and there was a significant difference between the two groups. Conclusion: There were differences in SLCO1B1 and APOE polymorphisms between the Mongolian and Han populations in Ordos. These may explain the differences in the incidence of cardiovascular diseases and the lipid-lowering efficacy of statins between the two populations.

Keywords:

References

1. Wang TT, Lin B, Cui WX et al. Clustering of cardiovascular risk factors and diabetes: a prospective cohort study on the Inner Mongolian population in China. Biomed. Environ. Sci. 31(10), 749–756 (2018).
MedlineGoogle Scholar
2. Mitchell JD, Fergestrom N, Gage BF et al. Impact of statins on cardiovascular outcomes following coronary artery calcium scoring. J. Am. Coll. Cardiol. 72(25), 3233–3242 (2018).
Medline CASGoogle Scholar
3. Guan ZW, Wu KR, Li R et al. Pharmacogenetics of statins treatment: efficacy and safety. J. Clin. Pharm. Ther. 44(6), 858–867 (2019 Dec).
MedlineGoogle Scholar
4. Zhang D, Cui G, Zhang XL. Effects of structural and genetic polymorphisms on the pharmacokinetics of statins. Chin. J. Pharm. 53(1), 6–9 (2018).
CASGoogle Scholar
5. Zhong Z, Wu H, Li B et al. Analysis of SLCO1B1 and APOE genetic polymorphisms in a large ethnic Hakka population in southern China. J. Clin. Lab. Anal. 32(6), e22408 (2018).
MedlineGoogle Scholar
6. Zeng HS, Wang DW. Guidelines for the Diagnosis and Treatment of Cardiovascular Internal Diseases (3rd Edition). Science Press, Beijing, China, 75–116 (2013).
Google Scholar
7. Wang FL, Meng XY, Chen ZX et al. Distribution of SLCO1B1 and APOE gene polymorphisms in Han Chinese patients with cardiovascular disease in Anhui Province and their significance in the clinical individualization of statins. Chinese Clinical Pharmacology and Therapeutics. 26(1), 40–48 (2021).
CASGoogle Scholar
8. Zhu JR, Gao RL, Zhao SP et al. Guidelines for the prevention and treatment of dyslipidemia in Chinese adults (2016 revised edition). Chin. J. Health Manage. 11(1), 7–28 (2017).
Google Scholar
9. Joint Committee on the Revision of the Guidelines for the Prevention and Treatment of Dyslipidemia in Chinese Adults. Guidelines for the prevention and treatment of dyslipidemia in Chinese adults (2016 revised edition). Chin. J. Circ. 31, 937–950 (2016).
Google Scholar
10. Superko HR, Momary KM, Li YH. Statins personalized. Med. Clin. North Am. 96(1), 123–139 (2012).
Medline CASGoogle Scholar
11. Birmingham BK, Bujac SR, Elsby R et al. Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect? Eur. J. Clin. Pharmacol. 71(3), 341–355 (2015).
Medline CASGoogle Scholar
12. Hou QT, Li SY, Li L et al. Association between SLCO1B1 gene T521C polymorphism and statin-related myopathy risk: a meta-analysis of case–control studies. Medicine (Baltimore) 94(37), e1268 (2015).
Medline CASGoogle Scholar
13. Sapkota B, Subramanian A, Priamvada G et al. Association of APOE polymorphisms with diabetes and cardiometabolic risk factors and the role of APOE genotypes in response to anti-diabetic therapy: results from the AIDHS/SDS on a South Asian population. J. Diabetes Complications 29(8), 1191–1197 (2015).
MedlineGoogle Scholar
14. Luo BC, Zhang J. Correlation analysis of APOE and SLCO1B1 gene polymorphisms with ischemic stroke. Stroke Neurol. Dis. 25(3), 264–267, 271 (2018).
Google Scholar
15. Bian SY, Wang YL, Liu HB. Relationship between SLCO1B1 and apolipoprotein E gene polymorphisms and blood lipids in patients with atherosclerotic cardiovascular disease risk stratification. Chin. J. Geriatr. Cardiovasc. Dis. 20(7), 676–680 (2018).
Google Scholar
16. Niu RB, Dong XX, Guo LP et al. Study on the relationship between SLCO1B1 and APOE gene polymorphisms and the risk of coronary heart disease in the Mongolian population. Clin. Exp. Hypertens. 43(8), 788–792 (2021).
Medline CASGoogle Scholar
17. Wang JW, Li Y, Qiao B et al. Analysis of SLCO1B1 and APOE gene polymorphisms and clinical significance in Han Chinese population in central China. J. Pract. Med. 34(18), 3041–3046 (2018).
Google Scholar
18. He S, Gou DY, Wang WY et al. Analysis of APOE and SLCO1B1 gene polymorphisms in Han Chinese patients with cardiovascular and cerebrovascular diseases in Hebei. Chin. J. Mod. Neurol. Dis. 21(5), 400–405 (2021).
Google Scholar
19. Liu CC, Liu CC, Kanekiyo T et al. ApolipoproteinE and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 9(2), 106–18 (2013).
Medline CASGoogle Scholar
20. Tang H, Yan XM, Hua YK et al. Distribution of APOE polymorphism in Chinese Yunnan Dehong Dai ethnic group. Chin. J. Med. Genet. 22(2), 224–226 (2005).
CASGoogle Scholar
21. Yan HY, Xie P, Li YL et al. Correlation of APOE and SLCO1B1 gene polymorphisms and genotype with lipid levels in Gansu. Chin. Heart J. 1, 46–49 (2019).
Google Scholar
22. Ruan HQ, Chen J, Xia MJ et al. Analysis of statin-related gene polymorphisms and clinical significance in Han Chinese population in Hainan. Int. J. Geriatr. 42(3), 143–147; 176 (2021).
Google Scholar
23. LaRosa JC, Pedersen TR, Somaratne R et al. Safety and effect of very low levels of low-density lipoprotein cholesterol on cardiovascular events. Am. J. Cardiol. 111(8), 1221–1229 (2013).
Medline CASGoogle Scholar
24. Liu HX, Cao LC, Zhou Y et al. Study on the distribution status of apolipoprotein E gene polymorphisms in different populations. Chin. J. Physicians 2(9), 530–531, 534 (2000).
Google Scholar

Vol. 23, No. 14

Metrics

Downloaded 82 times

History

Received 8 June 2022

Accepted 15 August 2022

Published online 8 September 2022

Published in print September 2022

Information

Keywords

Author contributions

Conception and design of the work: R Niu and L Guo; data collection: X Dong and L Pan; supervision: R Niu and L Guo; analysis and interpretation of the data: X Dong, L Pan, Y Hai and X Chen; statistical analysis: R Niu, L Guo and B Duan; drafting the manuscript: R Niu and L Guo; critical revision of the manuscript: R Niu, L Guo and DBS; approval of the final manuscript: all authors.

Financial & competing interests disclosure

This study was supported by Natural Science Foundation of Inner Mongolia Autonomous Region of China (2019MS08183) and Ordos Central Hospital in-hospital subject (EY2019001). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

This study was conducted in accordance with the Declaration of Helsinki and approved by the ethics committee of Ordos Central Hospital. All study subjects understood the purpose of the study and signed an informed consent form. The study protocol was approved by the ethics committee of Ordos Central Hospital and met the requirements of good clinical practice.

Availability of data & materials

All data generated or analyzed during this study are included in this published article.

PDF download